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Copyright © 2008 JCBN Summary Sepsis, as a severe systemic inflammatory response to bacterial infection,
represents a major clinical problem. It is characterized by the excessive production of reactive
oxygen species (ROS) both in the circulation and in the affected organs. The excessive
generation of ROS inevitably leads to oxidative stress in the microvasculature and has been
implicated as a causative event in a number of pathologies including sepsis. In this review, we
focus on the role of oxidative and nitrosative stress during the early onset of sepsis. Changes
in microvascular endothelial cells, the cell type that occurs in all organs, are discussed. The
mechanisms underlying septic induction of oxidative and nitrosative stresses, the functional
consequences of these stresses, and potential adjunct therapies for microvascular dysfunction
in sepsis are identified.
Key Words:systemic inflammation, oxidant stress, anti-oxidants
Introduction
Sepsis is a complex inflammatory response of the host to
bacterial infection. It frequently occurs after trauma, hemor-
rhage, burn or abdominal surgery, which cause a systemic
inflammatory response syndrome (SIRS) [1,  2]. Without
timely and aggressive therapeutic intervention, sepsis often
leads to multiple organ dysfunction and ultimately to death
[3]. SIRS and sepsis remain the prime causes of death in
intensive care units worldwide, with mortality rates ranging
between 30 and 70% [4, 5].
The initiating event in sepsis may be release of endotoxins
(i.e., bacterial cell wall lipopolysaccharides (LPS)) from
Gram-negative and Gram-positive pathogenic bacteria [6].
LPS triggers activation of inflammatory cells, such as
polymorphonuclear leukocytes (neutrophils; PMN), mono-
cytes/macrophages and lymphocytes. LPS thereby triggers
cellular and humoral aspects of the inflammatory immune
response. It is generally agreed that it is not the bacterial
infection itself, but rather the inflammatory response to
infection that is the predominant determinant of outcome in
sepsis [7, 8].
One of the key features of sepsis is tissue infiltration by
phagocytic cells [9–13]. In this scenario, PMN and mono-
cytes/macrophages respond to septic stimulation by pro-
ducing reactive oxygen species (ROS) (e.g., superoxide,
hydrogen peroxide) and reactive nitrogen species (RNS)
(e.g., nitric oxide) [14]. In addition, PMN release granular
enzymes (e.g. elastase, cathepsin) and the myeloperoxidase
(MPO)-derived oxidant, hypochlorous acid (HOCl). All
these components may contribute to PMN/macrophage-
mediated killing of the bacteria. However, if produced in
excess during SIRS and sepsis, the ROS, RNS and pro-
teolytic enzymes cause microvascular dysfunction followed
by organ dysfunction (Fig. 1).
An inflammatory response to septic stimuli is crucial for
host defense, because it up-regulates anti-inflammatoryG. Cepinskas et al.
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mediators (e.g., IL-1 receptor antagonist, IL-4, IL-10) and
antioxidant enzymes (e.g., catalase, glutathione peroxidase,
manganese superoxide dismutase). However, excessive
production of pro-inflammatory mediators in sepsis over-
whelms the anti-inflammatory signaling. This results in
suppression of innate immune functions (especially those of
PMN) and leads to immunoparalysis and subsequently to
increased susceptibility to infection [15].
It is important to note that, besides immune cells,
microvascular endothelial cells also become activated in
sepsis and may contribute to amplification of the inflam-
matory response [6, 11, 16]. In support to this hypothesis, it
has been shown that septic stimuli (e.g., LPS, TNF-α)
initiate activation of transcription factors such as NFκB and
AP-1, resulting in transcriptional activation of multiple
genes. This leads to the release of pro-inflammatory cyto-
kines (e.g. TNF-α, IL-1β etc), and increased expression of
adhesion molecules (e.g. E-selectin, ICAM-1, VCAM-1)
and chemokines by endothelial cells [11, 17–19]. A key role
of ROS/RNS in modulation of the endothelial cell pro-
inflammatory phenotype has been highlighted previously
[20] (Fig. 1).
Given the complexity of SIRS and sepsis, it is perhaps not
surprising that little progress has been made in improving
outcome [15]. Efforts to block one or other component of the
sepsis-associated inflammatory pathways have had little
impact on patient survival. Of many drugs tested, few have
demonstrated efficacy [21–24]. Future advances in sepsis
therapy will depend on improved understanding of the
underlying pathophysiology. In this review, we will focus on
the early events in the response to septic stimuli of micro-
vascular endothelial cells, the cell type that occurs in all
organs.
Microvascular Changes in Sepsis
The endothelium is a continuous single-cell lining of the
cardiovascular system. It forms an interface between blood
and tissues. In health, the endothelium provides a non-
adhesive and anti-thrombotic surface for blood-born compo-
nents, including circulating leukocytes. However, during
sepsis, the microvascular endothelium is activated to a pro-
adhesive and pro-thrombotic phenotype. In addition, septic
endothelium becomes both a target and a source of ROS and
RNS, and it thereby contributes to the onset of organ
dysfunction [19, 25].
Clinically, sepsis is characterized by a severe micro-
vascular dysfunction that persists despite fluid resuscitation.
It has been suggested that microvascular dysfunction under
septic conditions is closely related to: (i) arteriolar hypo-
responsiveness to vasoconstrictors and vasodilators, in-
cluding endothelium-dependent vasodilators; (ii) increased
capillary permeability that manifests as a breakdown of the
microvascular endothelial barrier; (iii) loss of the anti-
adhesive function of endothelial surfaces; (iv) coagulopathy;
(v) decreased density of perfused capillaries and elevated
proportion of non-perfused capillaries, even in fluid-
Fig. 1. Schematic diagram of cellular responses in sepsis.
Sepsis-related inflammatory mediators (e.g. LPS, TNF-
α, etc.) present in blood plasma directly activate micro-
vascular endothelial cells and leukocytes with respect to
the increased production of oxidants, activation of
inflammation-relevant transcription factor, NFκB, and
up-regulation of pro-adhesive phenotype, resulting in an
increased neutrophilic leukocyte (PMN) migration/accu-
mulation in the tissues and microvascular dysfunction
(solid dark arrows). That, in turn, leads to activation of
residential macrophages and organ-specific parenchymal
cells, which results in feedback activation of the micro-
vascular endothelial cells and leukocytes (dark arrows).
Subsequently, these cells further impair microvascular
function, allowing pro-inflammatory mediators directly
access from the blood to the interstitium (solid white
arrow). Because of the systemic nature of the septic
response, inflammation in each individual organ may be
stimulated repeatedly by pro-inflammatory mediators
that are released into the circulation by remote organs. If
unchecked, sepsis leads to the multiple organ dysfunc-
tion and failure.Oxidative Stress and Microvascular Dysfunction
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resuscitated patients with adequate arterial blood oxygen-
ation and cardiac output [6, 26–33].
Microvascular dysfunction is a strong predictor of death
in septic patients [29]. Tissue hypoxia develops because the
diffusion distance for oxygen increases between blood and
tissue cells [27]. This may explain why approximately one-
third of patients with severe sepsis (i.e., sepsis with at least
one organ failure or dysfunction) die of organ failure even
when shock is prevented by fluid resuscitation and admin-
istration of vasopressor drugs [29, 34, 35].
Sources and Actions of Reactive Oxygen and
Nitrogen Species in Endothelium During Sepsis
Endothelial cells are influenced by ROS that are produced
at accelerated rates during sepsis [36]. ROS from activated
neutrophils act as paracrine agents to alter endothelial cell
function. Additionally, endothelial cells increase intra-
cellular ROS production. For example, superoxide is a ROS
that is synthesized in endothelial cells by the mitochondrial
electron transport chain, xanthine oxidase, uncoupled nitric
oxide synthases (NOS) and NADPH oxidases.
Bacterial bloodstream infection exposes endothelial cells
to blood-borne endotoxins (e.g., E. coli lipopolysaccharide,
LPS) and inflammatory cytokines (e.g., interferon-γ, IFNγ).
The cells respond to this septic insult by activating endo-
thelial NADPH oxidases that synthesize intracellular super-
oxide. Indeed, NADPH oxidase activity is the principal
source for stimulated production of superoxide in micro-
vascular endothelial cells exposed to septic insult [36–38].
For example, in microvascular endothelial cell cultures,
septic insult (LPS and IFNγ in combination; LPS + IFNγ)
increases superoxide levels within 2 h [37]. NADPH oxidase
evidently is the principal source because the rise in super-
oxide levels is abolished by NADPH oxidase inhibitors
(apocynin and diphenylene iodonium) but not by inhibitors
of mitochondrial respiration (rotenone), xanthine oxidase
(allopurinol) or NOS (L-NAME) [37]. Longer incubation
(12 h) with LPS + IFNγ increases NADPH oxidase activity
and NADPH oxidase protein expression [37]. Increases in
intracellular ROS, whether caused by acute stimulation of
NADPH oxidase or by entry of extracellular ROS, induce
the expression of NADPH oxidase subunits that sub-
sequently assemble and produce more ROS [39].
Dismutation of superoxide forms hydrogen peroxide and
nitration of superoxide forms peroxynitrite. Compared to
superoxide, both hydrogen peroxide and peroxynitrite are
strong oxidants and the latter is also a nitrosative stressor.
Thus, activation of NADPH oxidase during sepsis induces
oxidative and nitrosative stress in endothelial cells. The
consequences of the increased levels of intracellular
oxidants are described next.
Effects of Oxidative and Nitrosative Stress on
Microvascular Endothelial Function in Sepsis
Normally endothelial cells regulate vascular smooth
muscle tone by basal rates of production of endothelial nitric
oxide synthase (eNOS)-derived nitric oxide and prosta-
glandin endoperoxide H2 synthase-1 (PGHS)-1-derived
prostacyclin (PGI2) [40]. Nitric oxide directly enters the
smooth muscle cell and activates soluble guanylyl cyclase,
thereby raising intracellular cGMP. PGI2 stimulates
adenylyl cyclase to raise intracellular cAMP. cGMP and
cAMP then mediate smooth muscle relaxation. However,
septic insult increases production of superoxide that reacts
with nitric oxide to form peroxynitrite that nitrates and
inactivates endothelial PGI2 synthase, which can then no
longer synthesize PGI2. Superoxide may also decrease the
effective cellular level of nitric oxide below that required
for guanylyl cyclase activation [40].
NADPH oxidase-derived oxidants (i.e., hydrogen per-
oxide and peroxynitrite) oxidize tetrahydrobiopterin, which
is a cofactor for synthesis of nitric oxide by NOS enzymes
[41, 42]. The loss of tetrahydrobiopterin (due to its oxida-
tion) uncouples eNOS, so that the enzyme synthesizes
superoxide rather than nitric oxide [41]. This is detrimental
to blood flow in capillaries, which depends on nitric oxide
synthesized locally by eNOS [43]. Further, ROS activate
intracellular redox signaling pathways to increase adhesion
of leukocytes, platelets and red blood cells to the endo-
thelium and thereby precipitate capillary blood flow cessa-
tion [44–46].
Increased permeability of the endothelium occurs in
multiple organs during sepsis, leading to plasma extravasa-
tion and edema formation. This causes loss of blood volume
and progression of septic shock (i.e., severe sepsis with
hypotension unresponsive to fluid resuscitation) [47]. Basal
nitric oxide production by eNOS is necessary for mainte-
nance of the endothelial barrier function [48–50]. The
protective effect of nitric oxide is diminished during the
inflammatory response due to the simultaneous production
of superoxide. The source of this superoxide is likely the
NADPH oxidase that is co-localized with eNOS in sub-
cellular compartments within endothelial cells [51]. Indeed,
there is experimental evidence that NADPH oxidase-derived
ROS mediate endothelial barrier failure [52]. Reaction of
superoxide with nitric oxide forms peroxynitrite. The latter
causes lipid peroxidation, oxidation of sulfhydryl groups
and nitration of tyrosine residues. In particular, nitration of
cytoskeletal proteins by peroxynitrite appears to be a key
step for endothelial barrier dysfunction [53, 54].
The oxidants that arise from NADPH oxidase activity
(e.g., hydrogen peroxide formed by dismutation of super-
oxide) exert prolonged redox signaling effects that enhance
induction of inducible nitric oxide synthase (iNOS) in septicG. Cepinskas et al.
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blood vessels and endothelial cells [33,  37,  52,  55–57].
iNOS synthesizes abundant nitric oxide that in turn reacts
with superoxide resulting in an excess production of per-
oxynitrite. This inevitably leads to the further impairment of
microvascular function. For instance, iNOS expression in
omental arteries of septic patients is associated with a
subnormal arteriolar response to norepinephrine that can be
normalized by the non-selective NOS inhibitor N(G)-
methyl-l-arginine (L-NMMA) [58]. In addition, expression
of the vascular adhesion molecule, E-selectin (a marker of
vascular pro-inflammatory phenotype) is significantly
abridged in the organs of iNOS-deficient mice challenged
with LPS (Fig. 2) [59]. Important to note, that interfering
with production of peroxynitrite by pretreating cultured
endothelial cells with the peroxynitrite decomposition
catalyst 5,10,15,20-tetrakis(4-sulfonatophenyl)prophyrinato
iron [III] (FeTPPS) also reduces activation of nuclear factor
NFκB and subsequent up-regulation of NFκB-dependent
expression of E-selectin (Fig. 3) [59].
The oxidants produced in endothelial cells during sepsis
also induce expression of tissue factor [30, 60]. This trans-
membrane glycoprotein (formerly known as thrombo-
plastin) functions as the primary cellular initiator of blood
coagulation  in vivo [ 60]. Because endothelial cells and
monocytes do not express tissue factor under physiological
conditions, there is no appreciable contact of cellular tissue
factor with the circulating blood. However, these cells do
express tissue factor when exposed to inflammatory cyto-
kines and this response contributes to coagulopathy in
sepsis. When tissue factor is exposed to blood, it forms a
high-affinity complex with coagulation factors, leading to
the formation of an insoluble fibrin clot. Coagulation is
activated rapidly after septic insult and results in diffuse
microvascular clot formation that may disrupt blood flow in
capillary beds [28,  30,  60]. NADPH oxidase-derived
oxidants also stimulate the activation of the heterodimeric
transcription factor hypoxia inducible factor-1 (HIF-1) in
endothelial cells [61]. Normally the HIF-1α subunit has a
short half-life because it is covalently modified by HIF-1
prolylhydroxylase, which targets HIF-1α for proteolysis by
Fig. 2. Expression of E-selectin in the small intestine and lungs of LPS-challenged wild-type (WT) and iNOS-deficient (iNOS−/−)
mice. Values are mean ± SE (n = 5 in each group). *p<0.05 vs control; †p<0.05 between LPS wild-type and LPS iNOS−/−
mice. (Adopted from Lush CW et al., Gastroenterology, 2003. Ref. 59).
Fig. 3. Pretreatment of cultured endothelial cells (HUVEC) with peroxynitrite decomposition catalyst, FeTPPS for 1 h attenuates
inflammatory response with respect to LPS-induced activation of nuclear factor κB, NFκB (EMSA) (A) and subsequent surface
expression levels of E-selectin (B). (A) A representative EMSA image from 3 independent experiments. (B) Values are
mean ± SE (n =3 ) .  * p<0.05 compared to control. #p<0.05 compared to LPS-treated group. (Adopted from Lush CW et al.,
Gastroenterology, 2003, Ref. 59).Oxidative Stress and Microvascular Dysfunction
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the ubiquitin-proteosome system. However, oxidants inhibit
prolylhydroxylase activity and thereby allow HIF-1α to
dimerize with the HIF-1β subunit. The dimerization acti-
vates HIF-1 to translocate to the nucleus, bind DNA and
promote expression of iNOS and other inflammatory genes
[62–64].
Potential Adjunct Therapy for Microvascular Dys-
function in Sepsis
Sepsis is treated by controlling the source of infection,
administering antimicrobial (e.g., antibiotic) therapy, assuring
hemodynamic support with fluid resuscitation and vaso-
pressor drugs, inducing sedation or analgesia as needed;
and providing adequate nutrition [65]. Despite these inter-
ventions, approximately one-third of all patients with severe
sepsis die before leaving hospital [66]. Therefore, the
development of additional therapies is a research topic of
urgent priority.
Septic patients may benefit from adjunct therapies that
target microvascular dysfunction. This hypothesis is based
on the observation that many patients with sepsis die of
organ failure despite adequate arterial blood oxygenation
and cardiac output [29, 34, 35]. Further, survival is improved
by treatments that improve microvascular function (e.g.,
antioxidants, iNOS deficiency, and tissue factor pathway
inhibitor) in animal models of polymicrobial sepsis [33, 67–
70]. Several potential therapies that target septic micro-
vascular dysfunction are discussed next.
The administration of activated protein C (APC) to septic
patients is a recently introduced therapy. APC exerts anti-
coagulant effects. Further, the adherence of leukocytes to
arteriolar and venular endothelium is strongly diminished
by activated protein C infusion, which is associated with an
increased density of blood-perfused capillaries in an animal
model of SIRS [71]. APC also induces rearrangement of
endothelial cells’ actin cytoskeleton and thereby stabilizes
endothelial barrier function [72]. Indeed, therapeutic benefit
of APC in sepsis may be largely due to augmentation of
endothelial barrier function [72].
Unfortunately, any benefit from APC may be outweighed
by adverse effects, especially an increased rate of hemor-
rhage [73]. A recent Cochrane review recommended that
APC should not be given to patients at low risk of death or to
pediatric patients [74]. The review also concluded that the
evidence supporting APC use in patients with severe sepsis
and at high risk of death was very weak [74]. However,
chemical variants of APC have been synthesized that may
retain therapeutic efficacy while reducing the risk of
bleeding. Experiments in mouse sepsis models, for example,
show that survival is increased by a recombinant APC
variant with normal cell signaling activity but <10% anti-
coagulant activity [75]. Therefore, a therapy may be
developed in future that treats septic patients with APC
variants that have normal cell signaling but reduced anti-
coagulant activities.
A second intervention that has been tested in critically ill
patients is administration of the nonselective NOS inhibitor
N(G)-methyl-l-arginine (L-NMMA). A phase III clinical
trial of L-NMMA in patients with septic shock was termi-
nated early because of increased mortality, but post hoc
analysis indicated an overall survival benefit for low-dose L-
NMMA [76]. The adverse effect of high-dose L-NMMA
may have been due to inhibition of the eNOS necessary for
microvascular homeostasis [77].
Vitamin C injection is also a candidate therapy [26, 78,
79]. In a randomized, prospective, double-blind, placebo-
controlled trial with 226 critically ill patients, 28-day
survival was increased in the patients who received
combined vitamin C and vitamin E by i.v. infusion compared
to those who did not [80]. Another large, randomized, pro-
spective trial demonstrated decreased incidence of organ
failure and shortened ICU stay for critically ill patients
who began receiving i.v. injections of combined vitamin C
(3 g/day for up to 28 days) and vitamin E within 24 h of
traumatic injury or major surgery [81]. Yet another random-
ized, prospective study reported decreased morbidity for
severely burned patients who were infused with an even
higher dose of vitamin C (1584 mg/kg/day) [82].
Studies of animal models have shown that vitamin C
prevents LPS-induced edema and hypotension [83,  84],
prolongs survival in experimental bacteremia [85], and
improves arteriolar responsiveness, arterial blood pressure,
capillary blood flow, liver function and survival in experi-
mental sepsis [26,  31–33,  86]. Therefore, the biological
plausibility of this intervention is discussed further in the
following paragraphs.
Vitamin C (ascorbic acid) dissociates to form ascorbate at
physiological pH [79]. Ascorbate functions as an antioxidant
and enzyme cofactor, becoming oxidized to dehydro-
ascorbic acid (DHAA) in the process. SIRS and sepsis lower
plasma ascorbate concentration [26, 31, 87–90]. Injection
i.v. of vitamin C can increase the amount of ascorbate
delivered to endothelial cells to a greater extent than can
oral ingestion [79].
As depicted in Fig. 4, ascorbate is transported into
microvascular endothelial cells by the specific transporter
SVCT2, while DHAA is taken up through facilitative
glucose transporters (GLUT) and then reduced to ascorbate
[79, 91–93]. The intracellular concentrations of ascorbate
thus achieved are 4–16 mM [37,  94]. This intracellular
ascorbate may protect microvascular function in two phases
of action: initially by inhibiting NADPH oxidase activation
and increasing eNOS activity, and subsequently by sup-
pressing expression of NADPH oxidase, iNOS and tissue
factor (Fig. 4).G. Cepinskas et al.
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Ascorbate in endothelial cells prevents tetrahydro-
biopterin oxidation, increases tetrahydrobiopterin content
and elevates synthesis of nitric oxide by eNOS [95, 96]. It is
important that ascorbate stimulates eNOS activity while
inhibiting iNOS expression. Studies of endotoxin induced
shock indicate that iNOS inhibition has little or no beneficial
effect in the presence of a failing eNOS system, because
some nitric oxide is needed to maintain adequate organ func-
tion [97].
An antioxidant role for vitamin C is supported by the
observation that ascorbate abrogates stimulation by septic
insult of superoxide production in microvascular endothelial
cells [37]. Intracellular concentrations of ascorbate inside
cells are high enough to prevent the reaction of superoxide
and nitric oxide that creates peroxynitrite [98] and to re-
reduce the oxidation products that peroxynitrite creates
when it reacts with cellular components [99]. Intracellular
ascorbate blocks induction by LPS + IFNγ or hydrogen
peroxide of endothelial NADPH oxidase activity, NADPH
oxidase protein expression and iNOS protein expression
[37, 55, 56, 100]. Injection i.v. of vitamin C also diminishes
iNOS mRNA expression in microvascular endothelial cells
and arterioles in an in vivo model of sepsis [32, 33].
Ascorbate is required for the optimal activity of the
proline and asparagine hydroxylases that control the tran-
scription factor HIF-1 [101]. Thus, intracellular ascorbate
lowers HIF-1 concentration to non-detectable levels [102].
Expression of HIF-1 sensitive genes, such as iNOS, is
similarly inhibited by ascorbate [32, 33, 102].
Bolus i.v. injection of 2 g vitamin C in human subjects
does not alter superoxide production by neutrophils [98].
Similarly, incubation of neutrophils with either ascorbic acid
or DHAA, to raise intracellular ascorbate concentration,
does not inhibit the production of extracellular ROS elicited
when these cells are subsequently challenged by inflam-
matory stimuli such as E. coli [103, 104]. This is important
because neutrophils use ROS to combat microbial patho-
gens.
There is cause for concern about potential adverse effects
of high-dose vitamin C injections. Under certain conditions
in vitro, ascorbic acid donates electrons to transition metals
(e.g. iron) that then catalyze the synthesis of hydrogen
peroxide [105, 106]. Injection i.v. of high-dose vitamin C is
not followed by elevation of oxidative stress biomarkers in
healthy human subjects [107], but its injection prior to
surgery increases oxidative modification of plasma lipids in
venous blood during the ischemic phase of surgery [108].
Because injection of high doses of vitamin C may increase
the risk of hemolysis in glucose-6-phosphate dehydrogenase
deficiency [109], patients should be prescreened for this
deficiency before administering i.v. vitamin C. Also,
because hyperoxaluric responses may occur [110] and
predispose susceptible individuals to nephrolithiasis, oxalate
measurements are recommended during long-term vitamin
C therapy.
In conclusion, therapies targeting microvascular dysfunc-
tion may have a significant impact on morbidity and
mortality in sepsis. Based on the low ascorbate concentra-
tions in septic patients, the improved microvascular function
and survival observed in septic animal models injected with
vitamin C, the improved outcomes observed in critically ill
patients administered i.v. vitamins C and E as adjuvant
therapy, and the preservation of neutrophils’ capacity to
produce ROS during exposure to supraphysiological extra-
cellular ascorbate levels, clinical trials of vitamin C injection
as an adjunct therapy in sepsis should be undertaken.
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